Indications5*
AZMACORT (triamcinolone acetonide) Inhalation Aerosol is indicated in the maintenance treatment of asthma as prophylactic therapy. AZMACORT is also indicated for asthma patients who require systemic corticosteroid administration, where adding AZMACORT may reduce or eliminate the need for the systemic corticosteroids.
AZMACORT is NOT indicated for the relief of acute bronchospasm.
Important Safety Information5*
- AZMACORT is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required, and in patients with hypersensitivity to any product ingredient.
- CAUTION: Adrenal insufficiency may occur when transferring patients from systemic steroids (see WARNINGS, Prescribing Information).
- Since the response of hypothalamic-pituitary-adrenal (HPA) function to inhaled corticosteroids is highly individualized, the physician should consider this when treating patients.
- Localized infections with Candida albicans have occurred infrequently in the mouth and pharynx.
- Patients should be advised to avoid exposure to chickenpox or measles and to obtain medical advice if exposed.
- Orally inhaled corticosteroids may cause a reduction in growth velocity when administered to pediatric patients. The long-term effects on final adult height are unknown. To minimize the systemic effects, each patient should be titrated to the lowest dose that controls symptoms.
- The most common reported adverse events occurring greater than placebo and in >3% of patients during clinical trials were sinusitis, pharyngitis, headache, flu syndrome, and back pain.
*AZMACORT (triamcinolone acetonide) Inhalation Aerosol, Prescribing Information, Abbott Laboratories.
